Evidence map›Paper›PMID 37861906›Full record

ArticleBulletin of experimental biology and medicine2023

Efficacy of Raphamin against Pneumococcal Infection: a Preclinical Study.

N V Petrova, A G Emelyanova, S A Tarasov, P G Aparin, V A Ledov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

N V PetrovaResearch Institute of General Pathology and Pathophysiology, Moscow, Russia. nataliyaapetrova89@gmail.com.
A G EmelyanovaResearch Institute of General Pathology and Pathophysiology, Moscow, Russia.
S A TarasovResearch Institute of General Pathology and Pathophysiology, Moscow, Russia.
P G AparinLLC "GRITVAK", Moscow, Russia.
V A LedovLLC "GRITVAK", Moscow, Russia.
Expedia Group (United States) · USFederal Medical-Biological Agency · RUResearch Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to evaluate the activity of Raphamin in a model of non-lethal pneumococcal infection caused by Streptococcus pneumoniae 3 in BALB/c mice. The drug or placebo was administered intragastrically 3 days prior to infection, 2 h before and 2 h post infection, and then for 3 full days, alone or in combination with antibiotic (amoxicil-lin/clavulanic acid). Raphamin monotherapy significantly decreased bacterial load in the lungs in comparison with placebo (p<0.05) which was comparable to the effect in antibiotic alone or combined with Raphamin. Raphamin prevented reproduction of Streptococcus pneumoniae in the lower respiratory tract and its combination with the antibiotic was safe and did not reduce the efficacy of amoxicillin/clavulanic acid.

Indexed as

Pneumococcal InfectionsAmoxicillin-Potassium Clavulanate CombinationAnimalsAnti-Bacterial AgentsClavulanic AcidMiceStreptococcus pneumoniaeAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsClavulanic AcidCD4 receptorIFNγMHC I and MHC II moleculesStreptococcus pneumoniae 3technologically processed antibodies

Identifiers

PMID37861906
OpenAlexW4387798762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.